{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:00:58Z","timestamp":1788184858327,"version":"build-2803163510"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013991","name":"Texas A and M University Health Science Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000209","name":"National Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007198","name":"US-Egypt Joint Board on Scientific and Technological Cooperation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023887","name":"Texas A&M University Health Science Center","doi-asserted-by":"publisher","award":["12150035558"],"award-info":[{"award-number":["12150035558"]}],"id":[{"id":"10.13039\/100023887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118219","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T20:09:31Z","timestamp":1759262971000},"page":"118219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Breaking barriers: Medicinal chemistry strategies and advanced in-silico approaches for overcoming the BBB and enhancing CNS penetration"],"prefix":"10.1016","volume":"301","author":[{"given":"Eneye D.","family":"Ajayi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elazazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6939-8462","authenticated-orcid":false,"given":"Hamed I.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118219_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00224","article-title":"Development and function of the blood-brain barrier in the context of metabolic control","volume":"11","author":"Haddad-T\u00f3volli","year":"2017","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118219_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183298","article-title":"Tight junction modulation at the blood-brain barrier: current and future perspectives","volume":"1862","author":"Hashimoto","year":"2020","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118219_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejpb.2022.02.004","article-title":"Is oral lipid-based delivery for drug targeting to the brain feasible?","volume":"172","author":"Brookes","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib5","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1177\/0271678X20985946","article-title":"Understanding the brain uptake and permeability of small molecules through the BBB: a technical overview","volume":"41","author":"Chowdhury","year":"2021","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2025.118219_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev-cellbio-100617-062608","article-title":"Development and cell biology of the blood-brain barrier","volume":"35","author":"Langen","year":"2019","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12951-025-03415-w","article-title":"Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood\u2013brain barrier permeability","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20517\/cdr.2018.02","article-title":"How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?","volume":"1","author":"Adrian","year":"2018","journal-title":"Cancer Drug Resistance"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib9","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1021\/acs.molpharmaceut.3c00715","article-title":"Dissimilar effect of P-Glycoprotein and breast cancer resistance protein inhibition on the distribution of erlotinib to the retina and brain in humans and mice","volume":"20","author":"Biali","year":"2023","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118219_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123108","article-title":"Approaches to CNS drug delivery with a focus on transporter-mediated transcytosis","volume":"20","author":"Abdul Razzak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12987-023-00489-2","article-title":"Breaking barriers: exploring mechanisms behind opening the blood\u2013brain barrier","volume":"20","author":"Stamp","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ejmech.2025.118219_bib12","series-title":"Drug Delivery Strategies in Neurological Disorders: Challenges and Opportunities","first-page":"27","article-title":"Challenges in drug development for neurological disorders","author":"Guha","year":"2023"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118219_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127503","article-title":"Methods to optimize CNS exposure of drug candidates","volume":"30","author":"Patel","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118219_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111571","article-title":"Novel derivatives of anaplastic lymphoma kinase inhibitors: synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib","volume":"182","author":"Radaram","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood\u2013brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-025-06448-9","article-title":"Application of EGFR-TKIs in brain tumors, a breakthrough in future?","volume":"23","author":"Feng","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118219_bib17","doi-asserted-by":"crossref","unstructured":"J. Huttunen, S. K. Adla, M. Markowicz-Piasecka, and K. M. Huttunen, \"Increased\/Targeted brain (Pro)Drug delivery via utilization of solute carriers (SLCs),\" Pharmaceutics, vol. 14, no. 6, doi: 10.3390\/pharmaceutics14061234.","DOI":"10.3390\/pharmaceutics14061234"},{"key":"10.1016\/j.ejmech.2025.118219_bib18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3389\/fphys.2020.00914","article-title":"Structure, function, and regulation of the blood-brain barrier tight junction in central nervous System disorders","volume":"11","author":"Lochhead","year":"2020","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2020.1840913","article-title":"Basic physiology of the blood-brain barrier in health and disease: a brief overview","volume":"9","author":"Kaya","year":"2021","journal-title":"Tissue Barriers"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ejmech.2025.118219_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6564585","article-title":"Blood-Brain barrier overview: structural and functional correlation","volume":"2021","author":"Alahmari","year":"2021","journal-title":"Neural Plast."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118219_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.32604\/or.2022.025696","article-title":"Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics","volume":"29","author":"Wang","year":"2021","journal-title":"Oncol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118219_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcdb.2014.11.004","article-title":"Transmembrane proteins of the tight junctions at the blood\u2013brain barrier: structural and functional aspects","volume":"38","author":"Haseloff","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1154641","article-title":"Junctional proteins of the blood-brain barrier: new insights into function and dysfunction","volume":"4","author":"Stamatovic","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ejmech.2025.118219_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3389\/fimmu.2020.01024","article-title":"Interaction of microglia and astrocytes in the neurovascular unit","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118219_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179510","article-title":"Connexins signatures of the neurovascular unit and their physio-pathological functions","volume":"23","author":"Vicario","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nn.4288","article-title":"Pericytes of the neurovascular unit: key functions and signaling pathways","volume":"19","author":"Sweeney","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00441-014-1811-2","article-title":"Novel insights into the development and maintenance of the blood-brain barrier","volume":"355","author":"Engelhardt","year":"2014","journal-title":"Cell Tissue Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1084\/jem.20180199","article-title":"Immune cells and CNS physiology: Microglia and beyond","volume":"216","author":"Norris","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118219_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-immunol-093019-110159","article-title":"Microglia and central nervous system-associated macrophages-from origin to disease modulation","volume":"39","author":"Prinz","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118219_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous System during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-Brain barrier: from physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118219_bib36","series-title":"StatPearls. Treasure Island (FL)","article-title":"Physiology, blood brain barrier","author":"Gawdi","year":"2024"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib37","doi-asserted-by":"crossref","first-page":"E1167","DOI":"10.1152\/ajpendo.00193.2003","article-title":"Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier","volume":"285","author":"O'Kane","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci. Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118219_bib39","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/ijms23073645","article-title":"Vascular permeability in diseases","volume":"23","author":"Wautier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118219_bib40","doi-asserted-by":"crossref","unstructured":"M. A. A. Saleh and E. C. M. de Lange, \"Impact of CNS diseases on drug delivery to brain extracellular and intracellular target sites in human: a \u201cWHAT-IF\u201d simulation Study,\" Pharmaceutics, vol. 13, no. 1, doi: 10.3390\/pharmaceutics13010095.","DOI":"10.3390\/pharmaceutics13010095"},{"key":"10.1016\/j.ejmech.2025.118219_bib41","doi-asserted-by":"crossref","unstructured":"F. Mo, A. Pellerino, R. Soffietti, and R. Rud\u00e0, \"Blood\u2013Brain barrier in brain tumors: biology and clinical relevance,\" Int. J. Mol. Sci., vol. 22, no. 23, doi: 10.3390\/ijms222312654.","DOI":"10.3390\/ijms222312654"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118219_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312654","article-title":"Blood-Brain barrier in brain tumors: biology and clinical relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood\u2013tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib44","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118219_bib45","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-011-0601-8","article-title":"Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer","volume":"29","author":"Taskar","year":"2012","journal-title":"Pharm. Res."},{"issue":"23","key":"10.1016\/j.ejmech.2025.118219_bib46","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12935-021-02263-6","article-title":"The structure of blood-tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases","volume":"21","author":"Ye","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood\u2013brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14336\/AD.2019.0519","article-title":"Alteration in the function and expression of SLC and ABC transporters in the neurovascular unit in Alzheimer's Disease and the clinical significance","volume":"11","author":"Jia","year":"2020","journal-title":"Aging Dis"},{"issue":"S5","key":"10.1016\/j.ejmech.2025.118219_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/alz.063948","article-title":"Blood-brain barrier permeability is increased in early Alzheimer's disease and correlates with brain microstructure","volume":"18","author":"Reas","year":"2022","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.ejmech.2025.118219_bib51","doi-asserted-by":"crossref","unstructured":"A. E. Alkhalifa, N. F. Al-Ghraiybah, J. Odum, J. G. Shunnarah, N. Austin, and A. Kaddoumi, \"Blood\u2013Brain barrier breakdown in alzheimer's disease: mechanisms and targeted strategies,\" Int. J. Mol. Sci., vol. 24, no. 22, doi: 10.3390\/ijms242216288.","DOI":"10.3390\/ijms242216288"},{"key":"10.1016\/j.ejmech.2025.118219_bib52","first-page":"11","article-title":"Pathways for small molecule delivery to the central nervous system across the blood-brain barrier","volume":"6","author":"Mikitsh","year":"2014","journal-title":"Perspect. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118219_bib53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mattod.2020.02.001","article-title":"Overcoming blood\u2013brain barrier transport: advances in nanoparticle-based drug delivery strategies","volume":"37","author":"Ding","year":"2020","journal-title":"Mater. Today"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/157015908785777210","article-title":"Brain endothelial cell-cell junctions: how to \"open\" the blood brain barrier","volume":"6","author":"Stamatovic","year":"2008","journal-title":"Curr. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tra.12645","article-title":"Endothelial cell barriers: transport of molecules between blood and tissues","volume":"20","author":"Yazdani","year":"2019","journal-title":"Traffic"},{"key":"10.1016\/j.ejmech.2025.118219_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.594672","article-title":"Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery","volume":"11","author":"Bernardo-Castro","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib57","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14728222.2015.1042364","article-title":"Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery","volume":"19","author":"Pardridge","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib59","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2025.118219_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119582","article-title":"Transcellular brain drug delivery: a review on recent advancements","volume":"586","author":"Azarmi","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neuron.2017.03.043","article-title":"Blood-Brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis","volume":"94","author":"Andreone","year":"2017","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib62","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.bcp.2013.03.022","article-title":"Transport of gabapentin by LAT1 (SLC7A5)","volume":"85","author":"Dickens","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1153568","article-title":"Nanoparticle transport across the blood brain barrier","volume":"4","author":"Grabrucker","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ejmech.2025.118219_bib64","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3762\/bjnano.11.72","article-title":"Key for crossing the BBB with nanoparticles: the rational design","volume":"11","author":"Lombardo","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib65","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/acs.jmedchem.2c01824","article-title":"Explaining blood\u2013brain barrier permeability of small molecules by integrated analysis of different transport mechanisms","volume":"66","author":"Cornelissen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/1062936X.2014.994562","article-title":"Qualitative and quantitative structure-activity relationship modelling for predicting blood-brain barrier permeability of structurally diverse chemicals","volume":"26","author":"Gupta","year":"2015","journal-title":"SAR QSAR Environ. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib67","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS drug design: balancing physicochemical properties for optimal brain exposure","volume":"58","author":"Rankovic","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib68","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1021\/mp400450m","article-title":"ADMET evaluation in drug discovery. 13. Development of in Silico prediction models for P-Glycoprotein substrates","volume":"11","author":"Li","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118219_bib69","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2022.08.051","article-title":"Recent advances in drug delivery and targeting to the brain","volume":"350","author":"Sethi","year":"2022","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40203-015-0012-3","article-title":"Computational modeling to predict the functions and impact of drug transporters","volume":"3","author":"Matsson","year":"2015","journal-title":"In Silico Pharmacology"},{"key":"10.1016\/j.ejmech.2025.118219_bib71","series-title":"Pharmacokinetic Optimization in Drug Research","first-page":"51","article-title":"Relations of molecular properties with drug disposition: the cases of gastrointestinal absorption and brain penetration","author":"van de Waterbeemd","year":"2001"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous System multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/acschemneuro.6b00273","article-title":"Technically extended MultiParameter optimization (TEMPO): an advanced robust scoring scheme to calculate central nervous System druggability and monitor lead optimization","volume":"8","author":"Ghose","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118219_bib74","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","article-title":"Strategies for structural modification of small molecules to improve blood-brain barrier penetration: a recent perspective","volume":"64","author":"Xiong","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10611869808997889","article-title":"Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors","volume":"6","author":"van de Waterbeemd","year":"1998","journal-title":"J. Drug Target."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118219_bib76","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.bmcl.2009.03.109","article-title":"Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower logD limits based on permeability","volume":"19","author":"Waring","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib77","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1021\/jm201136z","article-title":"Structural modifications that alter the P-glycoprotein efflux properties of compounds","volume":"55","author":"Hitchcock","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118219_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2020.01.009","article-title":"Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain","volume":"320","author":"Israel","year":"2020","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/cn200100h","article-title":"Knowledge-Based, Central Nervous System (CNS) lead selection and lead optimization for CNS drug discovery","volume":"3","author":"Ghose","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib80","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118219_bib81","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib82","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1745-7254.2005.00068.x","article-title":"Predictive model of blood-brain barrier penetration of organic compounds","volume":"26","author":"Ma","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cells12030421","article-title":"Computational approach to drug penetration across the blood-brain and blood-milk barrier using chromatographic descriptors","volume":"12","author":"Karolina","year":"2023","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.ejmech.2025.118219_bib84","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The blood\u2013brain barrier (BBB) Score","volume":"62","author":"Gupta","year":"2019","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118219_bib85","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.2174\/1381612826666200224112534","article-title":"Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning","volume":"26","author":"Morofuji","year":"2020","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118219_bib86","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.2174\/1567201819666220303102614","article-title":"Current status of in vitro models of the blood-brain barrier","volume":"19","author":"Shah","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejmech.2025.118219_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114816","article-title":"An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines","volume":"196","author":"P\u00e9rez-L\u00f3pez","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2025.118219_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2022.01.011","article-title":"In vitro blood brain barrier models: an overview","volume":"343","author":"Jagtiani","year":"2022","journal-title":"J. Contr. Release"},{"issue":"20","key":"10.1016\/j.ejmech.2025.118219_bib89","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118219_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112820","article-title":"Blood-brain barrier permeability study of ginger constituents","volume":"177","author":"Simon","year":"2020","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11237-022-09718-5","article-title":"Influence of chemical structure of molecules on blood\u2013brain barrier permeability on the pampa model","volume":"58","author":"Kosinska","year":"2022","journal-title":"Theor. Exp. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib92","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4155\/tde.15.32","article-title":"Molecular determinants of blood-brain barrier permeation","volume":"6","author":"Geldenhuys","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejmech.2025.118219_bib93","first-page":"43","volume":"17","author":"Soba\u0144ska","year":"2019"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib94","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bpj.2014.06.024","article-title":"A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations","volume":"107","author":"Carpenter","year":"2014","journal-title":"Biophys. J."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118219_bib95","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1021\/acs.molpharmaceut.6b00031","article-title":"Integrating in Silico and in vitro approaches to predict drug accessibility to the central nervous System","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib96","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib97","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/bioinformatics\/btaa918","article-title":"LightBBB: computational prediction model of blood-brain-barrier penetration based on LightGBM","volume":"37","author":"Shaker","year":"2021","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118219_bib98","first-page":"900","article-title":"Chris lipinski. Interview by Peter Kirkpatrick","volume":"11","author":"Lipinski","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib99","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/ci034205d","article-title":"Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates","volume":"44","author":"Adenot","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118219_bib101","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cpt.1402","article-title":"Imaging P-Glycoprotein function at the blood-brain barrier as a determinant of the variability in response to central nervous system drugs","volume":"105","author":"Bauer","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118219_bib102","article-title":"Lightgbm: a highly efficient gradient boosting decision tree","volume":"30","author":"Ke","year":"2017","journal-title":"Adv. Neural Inf. Process. Syst."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118219_bib103","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btad577","article-title":"A machine learning-based quantitative model (LogBB_Pred) to predict the blood-brain barrier permeability (logBB value) of drug compounds","volume":"39","author":"Shaker","year":"2023","journal-title":"Bioinformatics"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib104","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118219_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib106","article-title":"The penetration of therapeutics across the blood-brain barrier: classic case studies and clinical implications","volume":"5","author":"Banks","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2025.118219_bib107","series-title":"Introduction to Biological and Small Molecule Drug Research and Development","first-page":"81","article-title":"Chapter 3 - the small molecule drug discovery process \u2013 from target selection to candidate selection","author":"Stocks","year":"2013"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib108","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0250-474X.41446","article-title":"Strategies for enhanced drug delivery to the central nervous system","volume":"70","author":"Dwibhashyam","year":"2008","journal-title":"Indian J. Pharmaceut. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24086970","article-title":"Study of lipophilicity and ADME properties of 1,9-Diazaphenothiazines with anticancer action","volume":"24","author":"Morak-Mlodawska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118219_bib110","article-title":"Design principles for balancing lipophilicity and permeability in beyond rule of 5 space","volume":"19","author":"M\u00f6bitz","year":"2024","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib111","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1038\/s41598-025-90888-2","article-title":"Investigating blood\u2013brain barrier penetration and neurotoxicity of natural products for central nervous system drug development","volume":"15","author":"Kato","year":"2025","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118219_bib112","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.bmcl.2018.03.020","article-title":"Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability","volume":"28","author":"Zwicker","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118219_bib113","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1021\/jm501000a","article-title":"Acidic and basic drugs in medicinal chemistry: a perspective","volume":"57","author":"Charifson","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib114","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s13311-022-01228-5","article-title":"Current chemical, biological, and physiological views in the development of successful brain-targeted pharmaceutics","volume":"19","author":"Markowicz-Piasecka","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118219_bib115","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acs.jmedchem.8b02032","article-title":"Optimization of blood\u2013brain barrier permeability with potent and selective human neuronal Nitric oxide synthase inhibitors having a 2-Aminopyridine scaffold","volume":"62","author":"Do","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib116","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.drudis.2020.01.012","article-title":"Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space","volume":"25","author":"Caron","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118219_bib117","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10822-011-9478-1","article-title":"Qualitative prediction of blood\u2013brain barrier permeability on a large and refined dataset","volume":"25","author":"Muehlbacher","year":"2011","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118219_bib118","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1039\/D4MD00160E","article-title":"An analysis of the physicochemical properties of oral drugs from 2000 to 2022","volume":"15","author":"Pirie","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118219_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118193","article-title":"Truncated pyridinylbenzylamines: potent, selective, and highly membrane permeable inhibitors of human neuronal nitric oxide synthase","volume":"124","author":"Vasu","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118219_bib120","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous System-Penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118219_bib121","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1021\/acs.jmedchem.3c00348","article-title":"Discovery of a novel series of potent, selective, orally available, and brain-penetrable C1s inhibitors for modulation of the complement pathway","volume":"66","author":"Ikeda","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118219_bib122","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1021\/jm300119p","article-title":"Design and preparation of a potent series of hydroxyethylamine containing beta-secretase inhibitors that demonstrate robust reduction of central beta-amyloid","volume":"55","author":"Weiss","year":"2012","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118219_bib123","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1016\/j.bmcl.2013.02.083","article-title":"Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1)","volume":"23","author":"Nie","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118219_bib124","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118219_bib126","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1016\/j.bmcl.2015.04.074","article-title":"Discovery of a novel Kv7 channel opener as a treatment for epilepsy","volume":"25","author":"Davoren","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118219_bib127","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bmcl.2016.06.060","article-title":"Selective 5-HT2C receptor agonists: design and synthesis of pyridazine-fused azepines","volume":"26","author":"Green","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2018.12.029","article-title":"Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors","volume":"29","author":"Geneste","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118219_bib129","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1021\/acs.jmedchem.0c00395","article-title":"Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma","volume":"63","author":"Ensan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib130","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1021\/acs.jmedchem.4c03046","article-title":"BRF110, an orally active Nurr1-RXRalpha-Selective rexinoid, enhances BDNF expression without elevating triglycerides","volume":"68","author":"Asvos","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib131","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1038\/s41598-022-07247-8","article-title":"Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration","volume":"12","author":"Stalinska","year":"2022","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118219_bib132","doi-asserted-by":"crossref","first-page":"14432","DOI":"10.1021\/acs.jmedchem.4c01211","article-title":"Development of brain penetrant pyridazine pantothenate kinase activators","volume":"67","author":"Tangallapally","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118219_bib133","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54726","article-title":"3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation","volume":"9","author":"Lin","year":"2020","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22061006","article-title":"Novel tacrine-scutellarin hybrids as multipotent anti-alzheimer's agents: design, synthesis and biological evaluation","volume":"22","author":"Spilovska","year":"2017","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22081265","article-title":"Development of 2-Methoxyhuprine as novel lead for Alzheimer's Disease therapy","volume":"22","author":"Mezeiova","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118219_bib136","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejmech.2014.05.061","article-title":"Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents","volume":"82","author":"Ang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib137","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bmcl.2018.12.018","article-title":"Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: the neuroprotective and anxiolytic-like effects","volume":"29","author":"Huang","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118219_bib138","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1021\/acs.jmedchem.3c02308","article-title":"Discovery of conformationally constrained ALK2 inhibitors","volume":"67","author":"Gonzalez-Alvarez","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib139","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acsmedchemlett.5b00213","article-title":"Design, synthesis, and identification of silicon incorporated oxazolidinone antibiotics with improved brain exposure","volume":"6","author":"Seetharamsingh","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118219_bib140","doi-asserted-by":"crossref","first-page":"15477","DOI":"10.1021\/acs.jmedchem.3c01669","article-title":"Discovery of a hydroxylamine-based brain-penetrant EGFR inhibitor for metastatic non-small-cell lung cancer","volume":"66","author":"Hill","year":"2023","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118219_bib141","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.bmcl.2019.06.021","article-title":"Design of a brain-penetrant CDK4\/6 inhibitor for glioblastoma","volume":"29","author":"Bronner","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118219_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114028","article-title":"Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: a systematic study","volume":"228","author":"Rombouts","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118219_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115562","article-title":"Fibroblast growth factor receptor modulators employing diamines with reduced phospholipidosis-inducing potential","volume":"28","author":"Sakai","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib144","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bmcl.2011.10.115","article-title":"Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H(1)-antihistamines for insomnia","volume":"22","author":"Ravula","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118219_bib145","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1021\/jm2009138","article-title":"Highly potent, selective, and orally active phosphodiesterase 10A inhibitors","volume":"54","author":"Malamas","year":"2011","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118219_bib146","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective, brain penetrant, MTA-Cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-Deleted cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib147","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bmc.2017.11.038","article-title":"Identification of potent lysophosphatidic acid receptor 5 (LPA5) antagonists as potential analgesic agents","volume":"26","author":"Kawamoto","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118219_bib148","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/acsmedchemlett.9b00599","article-title":"Development of a potent brain-penetrant EGFR tyrosine kinase inhibitor against malignant brain tumors","volume":"11","author":"Tsang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118219_bib149","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1021\/acs.jmedchem.0c01199","article-title":"Leveraging an open science drug discovery model to develop CNS-Penetrant ALK2 inhibitors for the treatment of diffuse intrinsic pontine glioma","volume":"63","author":"Smil","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118219_bib150","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118219_bib151","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1021\/jm500610n","article-title":"Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists","volume":"57","author":"McCoull","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118219_bib152","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.bmc.2011.12.030","article-title":"Design, synthesis, biological evaluation, and comparative Cox1 and Cox2 docking of p-substituted benzylidenamino phenyl esters of ibuprofenic and mefenamic acids","volume":"20","author":"Hegazy","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21020201","article-title":"Design, synthesis, and biological evaluation of some novel pyrrolizine derivatives as COX inhibitors with Anti-Inflammatory\/Analgesic activities and low ulcerogenic liability","volume":"21","author":"Gouda","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118219_bib154","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejmech.2018.04.029","article-title":"Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition","volume":"152","author":"Malki","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118219_bib155","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bmc.2019.02.027","article-title":"Design and molecular modeling of novel P38\u03b1 MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds","volume":"27","author":"Abdelhafez","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118219_bib156","doi-asserted-by":"crossref","first-page":"15906","DOI":"10.1021\/acs.jmedchem.0c01647","article-title":"HER2 kinase-targeted breast cancer therapy: design, synthesis, and in vitro and in vivo evaluation of novel lapatinib congeners as selective and potent HER2 inhibitors with favorable metabolic stability","volume":"63","author":"Elwaie","year":"2020","journal-title":"J. Med. Chem."},{"issue":"30","key":"10.1016\/j.ejmech.2025.118219_bib157","doi-asserted-by":"crossref","first-page":"18872","DOI":"10.1021\/acsomega.0c02038","article-title":"Dual targeting of VEGFR2 and C-Met kinases via the design and synthesis of substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one derivatives as angiogenesis inhibitors","volume":"5","author":"Mohamady","year":"2020","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118219_bib158","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bmc.2006.10.029","article-title":"Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors","volume":"15","author":"Zheng","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118219_bib159","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2220570","article-title":"Design, synthesis, and antitumor efficacy of novel 5-deazaflavin derivatives backed by kinase screening, docking, and ADME studies","volume":"38","author":"Bedewy","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118219_bib160","unstructured":"Tamer A. Elwaie, Safinaz E. Abbas, Riham F. George, Enayat I. Aly, Zakaria Y. Abd Elmageed, Constantinos M. Mikelis, Hamed I. Ali, Novel Pyrrolotriazine-Based VEGFR-2 Kinase Inhibitors as Promising Sorafenib Analogues Targeting Hepatocellular Carcinoma, Unpublished data."},{"key":"10.1016\/j.ejmech.2025.118219_bib161","unstructured":"Maryam M. El Ganainy, Nashwa Mohamed Saber, Abu Zeid A. Hassanien, Ishaq Khan, Tamer A. Elwaie, Hamed I. Ali, HER2 & VEGFR Kinase-Dual Targeted Breast Cancer Therapy: Design, Synthesis, in Vitro Evaluation of Novel Quinazolines as Selective and Potent HER2 and VEGFR Inhibitors. Unpublished data."},{"key":"10.1016\/j.ejmech.2025.118219_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00265","article-title":"Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies","volume":"10","author":"Nikolic","year":"2016","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118219_bib163","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"issue":"26","key":"10.1016\/j.ejmech.2025.118219_bib164","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/jm060642i","article-title":"Structure\u2212Brain exposure relationships","volume":"49","author":"Hitchcock","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:05:33Z","timestamp":1773147933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":164,"alternative-id":["S0223523425009845"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118219","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking barriers: Medicinal chemistry strategies and advanced in-silico approaches for overcoming the BBB and enhancing CNS penetration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118219"}}